Results 161 to 170 of about 381,559 (266)

Diffuse Large B-Cell Lymphoma of the Ethmoid Sinus With Orbital Invasion: A Case Report. [PDF]

Cureus
Boualam Y, Sbai A, Benfadil D, Lachkar A.   +3 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Neutrophil Elastase as a Prognostic Biomarker and Driver of Tumor Progression in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Zheng X, Wang L, Liu Z, Qiu Y, Lu J, Shu L, Xu C, Zhou M, Miao Y, Cheng Y.   +9 more
europepmc   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Analysis of Prognostic Significance of CD47 Expression in Newly Diagnosed Large B Cell Lymphoma. [PDF]

Life (Basel)
Markovic O, Bukurecki I, Divac Pravdic A, Marinkovic G, Terzic T, Pavlovic M, Nikolic V, Vukosavljevic N, Cvetkovic Z.   +8 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Large B-cell Lymphoma With IRF4 Rearrangement in the Elderly. [PDF]

Cureus
Horaguchi R, Kikuchi S, Nabe Y, Kisamori S, Minemura T, Fujihira T, Ono K, Kamihara Y, Wada A, Sato T.   +9 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

Cells
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, Gaidano G.   +6 more
europepmc   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source